Northwestern Mutual Wealth Management Co. Sells 11,489 Shares of Cencora, Inc. $COR

Northwestern Mutual Wealth Management Co. lessened its holdings in shares of Cencora, Inc. (NYSE:COR) by 51.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,748 shares of the company’s stock after selling 11,489 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Cencora were worth $3,630,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of COR. Marshall Wace LLP boosted its position in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock valued at $623,534,000 after acquiring an additional 1,672,762 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Cencora by 528.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after buying an additional 1,241,186 shares during the last quarter. Viking Global Investors LP lifted its position in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after buying an additional 1,013,913 shares during the last quarter. Vanguard Group Inc. lifted its position in Cencora by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock worth $7,311,810,000 after buying an additional 916,506 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Cencora by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock worth $1,461,965,000 after buying an additional 821,098 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

Shares of Cencora stock opened at $275.01 on Monday. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The business’s 50 day simple moving average is $305.70 and its two-hundred day simple moving average is $336.74. The stock has a market capitalization of $53.51 billion, a P/E ratio of 21.09, a price-to-earnings-growth ratio of 1.27 and a beta of 0.64. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.Cencora’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period last year, the firm earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts forecast that Cencora, Inc. will post 17.79 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s payout ratio is 18.40%.

Cencora declared that its Board of Directors has approved a share buyback program on Thursday, May 21st that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 3.9% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of recent research reports. Citigroup dropped their target price on Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Barclays boosted their target price on Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Wells Fargo & Company dropped their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Finally, Evercore set a $360.00 target price on Cencora in a research report on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $380.25.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.